. Author manuscript; available in PMC: 2023 Oct 4.

Published in final edited form as: J Am Coll Cardiol. 2022 Oct 4;80(14):1287–1298. doi: 10.1016/j.jacc.2022.07.027

TABLE 3.

Association of a LPA-GRS With MACE Risk in the ASPREE Trial

MACE	Placebo Arm (n = 6,439)			Aspirin Arm (n = 6,376)
Events/participants	243 (3.8)			192 (3.0)
	HR	95% CI	P Value	HR	95% CI	P Value
Low LPA-GRS (Q1, 0%-20%)	Reference			Reference
Medium LPA-GRS (Q2-Q4, 21%-80%)	1.27	0.88-1.81	0.19	1.23	0.84-1.81	0.27
High LPA-GRS (Q5, 81%-100%)	1.70	1.14-2.55	0.008	1.41	0.90-2.23	0.13
P_interaction high LPA-GRS * aspirin			0.5487

Values are n (%) unless otherwise indicated. Bold indicates a statistically significance association detected (P < 0.05).

LPA-GRS = Lipoprotein(a) genomic risk score; Q = quintile; other abbreviations as in Table 2.